abrdn U.S. Small Cap Equity Fund on Travere Therapeutics, Inc.
Thesis
abrdn initiated Travere Therapeutics, which focuses on rare kidney and metabolic disorders. A foundational drug recently received approval for an additional kidney disease, expanding the commercial opportunity. The fund also sees upside from promising clinical candidates and believes strong commercial execution across these opportunities can support growth.
“We believe the combination of these opportunities with strong commercial execution could support growth.”